In oncology, developing breakthrough therapies is only half the battle—the real challenge is finding the patients who need them most. For pharmaceutical brand teams focused on rare mutations like NTRK, ROS1, IDH1, or RET, the problem isn’t whether these patients exist, but how to identify and reach them before disease progression or non-targeted therapies take over.
Traditional strategies fall short when target populations are scattered across tumor types, health systems, and testing workflows. OncoLens bridges this critical gap with AI-powered data extraction and lab-agnostic insights, enabling pharma teams to surface patients missed by standard channels and connect them to life-saving therapies in real time.
This resource explores how forward-thinking pharma organizations are shifting from reactive marketing to proactive patient identification, building ecosystems that drive precision care at scale.
Latest
